Prothelia is developing recombinant human Laminin-111 (rhLAM-111) for treatment of congenital muscular dystrophy type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin deficiency or LAMA2 deficiency.
| Website | http://www.prothelia.com |
| Revenue | $5 million |
| Employees | 3 (0 on RocketReach) |
| Founded | 2008 |
| Address | 30 Haven St, Milford, Massachusetts 01757, US |
| Phone | +1 508-561-9298 |
| Technologies |
JavaScript
,
HTML
,
PHP
+12 more
(view full list)
|
| Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering |
| Keywords | Muscular Dystrophy Treatment, Genetic Disease Treatment, Rare Disease Therapeutics, Pharmaceutical Development, Drug Development, Protein Therapeutics, Biotechnology, Clinical Trials, Regenerative Medicine, Pediatric Therapeutics, Orphan Drug Development, Cell Therapy, Gene Therapy |
| Competitors | Microsoft, SAP, Intuit, NetSuite, Odoo, Sage, Zoho, Epicor, Acumatica, Infor +42 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 5417 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies |
Looking for a particular Prothelia employee's phone or email?
The Prothelia annual revenue was $5 million in 2026.
Prothelia is based in Milford, Massachusetts.
The NAICS codes for Prothelia are [5417, 541714, 541, 54171, 54].
The SIC codes for Prothelia are [873, 87].